Productivity Losses and Costs in the Less-Common Systemic Autoimmune Rheumatic Diseases
Purpose of Review
We synthesised the literature on productivity losses and costs in the less-common systemic autoimmune rheumatic diseases: Sjogren’s syndrome (SjS), systemic sclerosis (SSc), poly/dermatomyositis (PM/DM), and systemic vasculitides (SV).
Of 29 studies located, 12 were published 2012 onwards (SSc = 6, SjS = 2, PM/DM = 2, SV = 2). In these, 25% of PM/DM, and 21–26% of SV, were work disabled, 22% of SSc stopped work within 3 years of diagnosis, and annual costs of absenteeism in SSc averaged $12,024 2017 USD. Very few studies reported on costs, presenteeism (working at reduced levels), or unpaid productivity loss. Across multiple systemic autoimmune rheumatic diseases (SARDs), major drivers of lost productivity were generalised items like pain, depression, and fatigue, rather than disease-specific factors.
Evidence suggests that work disability is common in SSc and strikes quickly. However, in SSc and other SARDs, more comprehensive estimates are needed, which include absenteeism and presenteeism from paid and unpaid work, costs, and drivers of productivity loss.
KeywordsWork disability Productivity loss Indirect costs Systemic sclerosis Sjogren’s syndrome Systemic vasculitis
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 6.Babigumira JB, Li M, Boudreau DM, Best JH, Garrison LP. Estimating the cost of illness of giant cell arteritis in the United States. Rheumatol Ther. 2017; Available from: http://link.springer.com/10.1007/s40744-017-0052-8Google Scholar
- 8.Abularrage CJ, Slidell MB, Sidawy AN, Kreishman P, Amdur RL, Arora S. Quality of life of patients with Takayasu’s arteritis. J Vasc Surg. 2008;47:131–6.Google Scholar
- 14.Decuman S, Smith V, Verhaeghe STL, Van Hecke A, De Keyser F. Work participation in patients with systemic sclerosis: a systematic review. Clin Exp Rheumatol. 2014;32:S-206–13.Google Scholar
- 20.•• Mandl T, Jørgensen TS, Skougaard M, Olsson P, Kristensen L-E. Work disability in newly diagnosed patients with primary Sjögren syndrome. J Rheumatol. 2017;44:209–15. Linked data from a clinical registry, with population-based social insurance data for incident cases (SjS and SSc) and a sample of the general population, in order to assess work disability longitudinally from the time of SjS/SSc diagnosis. CrossRefPubMedGoogle Scholar
- 33.Drummond MF, editor. Methods for the economic evaluation of health care programmes. 3. ed., reprint ed. Oxford: Oxford Univ. Press; 2007.Google Scholar
- 37.Clarke AE, Penrod J, Pierre YS, Petri MA, Manzi S, Isenberg DA, et al. Underestimating the value of women: assessing the indirect costs of women with systemic lupus erythematosus. Tri-Nation Study Group J Rheumatol. 2000;27:2597–604.Google Scholar
- 38.Bjerrum K, Prause JU. [Sociomedical aspects of primary Sjögren’s syndrome]. Ugeskr. Laeger. 1990;152:2113–6.Google Scholar
- 51.Boomsma MM, Bijl M, Stegeman CA, Kallenberg CG, Hoffman GS, Tervaert JW. Patients’ perceptions of the effects of systemic lupus erythematosus on health, function, income, and interpersonal relationships: a comparison with Wegener’s granulomatosis. Arthritis Rheum. 2002;47:196–201.CrossRefPubMedGoogle Scholar
- 55.• Regardt M, Welin Henriksson E, Sandqvist J, Lundberg IE, Schult M-L. Work ability in patients with polymyositis and dermatomyositis: an explorative and descriptive study. Work Read Mass. 2015;53:265–77. One of the first-known publications on productivity losses in PM/DM Google Scholar
- 58.Kawalec PP, Malinowski KP. The indirect costs of systemic autoimmune diseases, systemic lupus erythematosus, systemic sclerosis and sarcoidosis: a summary of 2012 real-life data from the Social Insurance Institution in Poland. Expert Rev. Pharmacoecon. Outcomes Res. 2015;15:667–73.CrossRefPubMedGoogle Scholar
- 59.• The BURQOL-RD Research Network, López-Bastida J, Linertová R, Oliva-Moreno J, Serrano-Aguilar P, Posada-de-la-Paz M, et al. Social/economic costs and health-related quality of life in patients with scleroderma in Europe. Eur J Health Econ. 2016;17:109–17. Recruited patients and their caregivers through patient organisations (instead of academic medical centres) and a rare diseases registry, and computed the productivity costs of SSc separately for seven European countries. CrossRefGoogle Scholar
- 61.•• Sandqvist G, Hesselstrand R, Petersson IF, Kristensen LE. Work disability in early systemic sclerosis: a longitudinal population-based cohort study. J Rheumatol. 2015;42:1794–800. Linked data from a clinical registry, with population-based social insurance data for incident cases (SjS and SSc) and a sample of the general population, in order to assess work disability longitudinally from the time of SjS/SSc diagnosis CrossRefPubMedGoogle Scholar
- 65.López-Bastida J, Linertová R, Oliva-Moreno J, Posada-de-la-Paz M, Serrano-Aguilar P. Social economic costs and health-related quality of life in patients with systemic sclerosis in Spain. Arthritis Care Res. 2013Google Scholar
- 67.Li X, Gignac MAM, Anis AH. The indirect costs of arthritis resulting from unemployment, reduced performance, and occupational changes while at work: Med. Care. 2006;44:304–10.Google Scholar
- 72.del Pino-Sedeño T, Trujillo-Martín MM, Ruiz-Irastorza G, Cuellar-Pompa L, de Pascual-Medina AM, Serrano-Aguilar P, et al. Effectiveness of nonpharmacologic interventions for decreasing fatigue in adults with systemic lupus erythematosus: a systematic review: treating fatigue in adults with SLE. Arthritis Care Res. 2016;68:141–8.CrossRefGoogle Scholar